Monday brought attention to reports that the US Food and Drug Administration grants approval for the use of inhaled insulin Afrezza in paediatric patients.
Supporting documents indicate Researchers and health authorities published findings adding to the scientific and medical evidence base.
Market and government data added specifics. The FDA approved inhaled insulin Afrezza for paediatric patients with type 1 and type 2 diabetes.
The record remains open to additional disclosures.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.tampabay28.com/news/local-news/news-tonight-top-headlines-and-weather-for-june-15-2026